Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743583 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL13305814 | 1.00 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL1861194 | 0.96 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL1861195 | 0.96 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL8365044 | 0.96 | CTSK (0.55) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL8354995 | 0.94 | CTSK (0.57) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL2773107 | 0.94 | CTSK (0.57) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL971301 | 0.87 | CTSK (0.51) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL971299 | 0.87 | CTSK (0.51) | CTSKCTSSCTSLCTSBKMT2A | |
| SCHEMBL8246683 | 0.87 | CTSK (0.54) | CTSKCTSSCTSLCTSBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919478-B1 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-1891089-B1 | HCV protease inhibitors in combination with food | MERCK SHARP & DOHME (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014083575-A2 | IMPROVED PROCESS FOR THE PREPARATION OF BOCEPREVIR INTERMEDIATE | MYLAN LABORATORIES LTD (IN) | 2014-06-05 | — | — | WO | disclosed |
| EP-2238100-B1 | PROCESS FOR THE SYNTHESIS OF 3-AMINO-3-CYCLOBUTYLMETHYL-2-HYDROXYPROPIONAMIDE OR SALTS THEREOF | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8211897-B2 | Inhibitors of cathepsin B | VIROBAY, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067379-B2 | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005107745-A1 | AN INHIBITOR OF HEPATITIS C | SCHERING CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005087721-A2 | COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005085242-A1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |